M Ventures
About M Ventures
M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany, investing in Biotechnology and Technology. They cover the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability. They invest in visionary companies that find new ways to treat challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way information is accessed, stored, processed, and displayed, and address complex challenges in sustainability and technology convergence.
Recent News
Lucidean Pulls In $18M Seed Round
Lucidean Raises $18M in Seed Financing
Johnson & Johnson’s Hematology Portfolio: Breakthroughs to Watch
FMC Raises €100M in Funding
Storm Therapeutics Secures $56M to Advance Cancer Drugs
FoRx Therapeutics Raises USD50M in Series A Financing
Vizgen Raises $48M in Funding
Cambridge Biotech STORM Therapeutics Raises $56M
M Ventures: Pharma CVC and Biotech Innovation in 2026
Recent Deals
NeoLogic Raises $10M Series A to Build Energy-Efficient CPUs for AI Data Centers
Lucidean Secures $18M Seed Funding Led by Entrada Ventures and Koch Disruptive Technologies
FMC Secures €100M Series C Funding Led by HV Capital
Disco Pharmaceuticals Secures €36M Seed Funding
Lucidean Secures $18M Seed Funding Led by Entrada Ventures and Koch Disruptive Technologies
FoRx Therapeutics Secures $50M Series A to Advance Precision Cancer Drug
